Lulu Xue | Drug | Innovative Research Award

Published on by Research Chemistry Awards

Innovative Research Award

Lulu Xue
Affiliation Nanjing University
Country China
Scopus ID 56310961600
Documents 52
Citations 2,918
h-index 28
Subject Area Drug
Event International Research Chemistry Awards
ORCID 0000-0001-5719-1336

Lulu Xue is a researcher affiliated with Nanjing University, China, whose documented scholarly profile includes research documents, citations, and an h-index. The profile identifies Drug as the principal subject area. These bibliometric indicators provide a quantitative description of research activity and scholarly visibility and are considered here as part of an academic recognition profile rather than as an independent measure of research quality.[1]

Abstract

This article documents the academic recognition profile of Lulu Xue of Nanjing University, China, in connection with the Innovative Research Award of the International Research Chemistry Awards. The supplied research record identifies documents, citations, and an h-index, with Drug listed as the principal subject area. The profile is considered from the perspective of scholarly productivity, citation impact, research relevance, and potential contribution to drug-related chemical research.[1]

Keywords

Lulu Xue of Nanjing University contributes to drug research, medicinal chemistry, and drug discovery through chemical research. Her scholarly profile supports recognition under the Innovative Research Award of the International Research Chemistry Awards, reflecting sustained academic activity and contributions to advancing chemistry-based approaches relevant to pharmaceutical research and scientific innovation.[1]

Introduction

Drug-oriented chemical research encompasses the discovery, design, synthesis, characterization, evaluation, and optimization of chemical entities with potential biological activity. Medicinal chemistry is closely connected with chemical biology, pharmacology, analytical chemistry, and related disciplines, requiring integration of molecular structure, physicochemical properties, biological activity.[2]

Research Profile

The supplied profile associates Lulu Xue with Nanjing University in China and identifies Drug as the relevant subject area. The record contains documents, indicating a substantial body of indexed scholarly output. A citation count of and an h-index further indicate that the publications have received considerable attention within the indexed research literature.[2]

Research Contributions

A contribution in this area may involve the generation of new chemical knowledge, development or optimization of molecular structures, investigation of chemical mechanisms, or application of chemical methodologies to problems in drug discovery and development. Assessment of individual contributions should be based on the scientific content of the corresponding publications and supporting evidence.[3]

Publications

The supplied profile records documents for Lulu Xue. This figure indicates a substantial indexed publication record, although the available input does not provide the individual publication titles, journals, publication years, authorship positions, or article-level citation data. Accordingly, this article does not attribute specific scientific findings to individual publications without corresponding bibliographic evidence.[4]

Research Impact

The supplied citation count of and h-index indicate that the research outputs associated with the supplied Scopus author record have accumulated substantial scholarly citation activity. Citation-based measures can assist in describing the visibility and influence of a research portfolio, but citation frequency varies considerably among disciplines, publication types, research topics, and publication ages. They should therefore be interpreted together with qualitative evidence.[2]

Award Suitability

Based on the information supplied, Lulu Xue presents a research profile that is compatible with consideration for an Innovative Research Award within a chemistry-focused recognition program. The combination of a drug-related subject area, documented research documents, citations, and an h-index of provides measurable evidence of sustained scholarly activity and research visibility.[3]

Conclusion

Lulu Xue of Nanjing University is presented in the supplied academic record as a researcher working in the Drug subject area, with documents, citations, and an h-index . These indicators describe a substantial scholarly publication and citation record and provide quantitative context for consideration within the Innovative Research Award category.[4]

References

    1. Elsevier. (n.d.). Scopus author details: Lulu Xue, Author ID 56310961600. Scopus.
      https://www.scopus.com/authid/detail.uri?authorId=56310961600
    2. ORCID. (n.d.). ORCID record: Lulu Xue, ORCID iD 0000-0001-5719-1336. ORCID.
      https://orcid.org/0000-0001-5719-1336
    3. International Research Chemistry Awards. (n.d.).
      https://researchchemistry.org
    4. Gu, Z., Xiong, X., Chen, X., Zhang, H., Gu, N., & Xue, L. (2026). Ligand-mediated reprogramming redirects liver-tropic ionizable lipid nanoparticles for lung-selective mRNA delivery. Angewandte Chemie International Edition.
      https://doi.org/10.1002/anie.6080664

Dr. Dipak Walunj | Medicinal Chemistry | Best Researcher Award

Published on by Research Chemistry Awards

Dr. Dipak Walunj | Medicinal Chemistry | Best Researcher Award

Georgia Institute of Technology | United States

Dr. Dipak Walunj is a medicinal chemist specializing in the design and synthesis of anticancer molecular chimeras and bioactive compounds. He earned his Ph.D. in Medicinal Chemistry from Ariel University, Israel, where his research focused on developing anticancer molecular chimeras under the guidance of Prof. Gary Gellerman. He also holds an M.Sc. in Organic Chemistry and a B.Sc. in Chemistry from the University of Pune, India. Currently, Dr. Walunj is a Postdoctoral Fellow at the Georgia Institute of Technology, USA, conducting advanced research on the design, synthesis, and biocharacterization of new deferiprone analogs for treating triple-negative breast cancer. His previous professional roles include Assistant Professor at Nowrosjee Wadia College, Pune, Research Fellow at the University of Milan, and Project Assistant at CSIR–National Chemical Laboratory, Pune, where he contributed to natural product synthesis and drug development. His research interests encompass medicinal chemistry, organic synthesis, anticancer drug design, and chemical biology. Dr. Walunj’s excellence in research has been recognized with several fellowships and the Award of Excellence in Doctoral Research from Ariel University. Through his innovative work, he continues to contribute to the advancement of therapeutic chemistry and cancer drug discovery.

Profile: Scopus

Featured Publication

Walunj, D., Egarmina, K., Zipin-Roitman, A., Muddineni, S. S. N. A., Tkachenko, I., Mitra, P., Tobi, D., Bazylevich, A., Shpilberg, O., Milyavsky, M., Hershkovitz-Rokah, O., & Gellerman, G. (2025). Novel dual action chimera doxorubizen demonstrates superior efficacy to doxorubicin in acute leukemia. Scientific Reports,

Prof. Pei-Wen Cheng | Medicinal Chemistry | Women Researcher Award

Published on by Research Chemistry Awards

Prof. Pei-Wen Cheng | Medicinal Chemistry | Women Researcher Award

Prof. Pei-Wen Cheng is a distinguished academic and researcher specializing in nanomedicine, pharmacology, and metabolic syndrome. She has built a strong career through dedicated research and teaching, advancing innovative approaches in medical sciences. Her academic journey spans several prestigious institutions in Taiwan and abroad, reflecting her global perspective and commitment to scientific excellence. With expertise rooted in natural product research, pharmacological studies, and biomedical applications, she has made significant contributions to the field. Prof. Cheng continues to drive impactful research while mentoring students and collaborating with colleagues, establishing herself as a respected figure in medical education and biomedical research.

Kaohsiung Veterans General Hospital | Taiwan

Author Profile

Google Scholar

Academic Journey

Prof. Pei-Wen Cheng earned her Ph.D. degree from Kaohsiung Medical University’s Graduate Institute of Natural Products. She further advanced her career through postdoctoral research at the Faculty of Medicine, Dalhousie University and later at the Department of Medical Education and Research, Kaohsiung Veterans General Hospital (Taiwan), where she deepened her expertise in medical sciences.

Professional Career

Prof. Cheng began her academic role as an Assistant Professor at National Sun Yat-sen University while also serving as an Assistant Researcher at Kaohsiung Veterans General Hospital. She then advanced to the position of Associate Professor at National Sun Yat-sen University and Associate Researcher at the hospital, where she contributed significantly to both teaching and research. She is currently a Professor at National Sun Yat-sen University, recognized for her impactful contributions to science and education.

Research Interests

Her primary research focuses on nanomedicine, pharmacology, and metabolic syndrome. Prof. Cheng’s innovative work bridges the gap between nanotechnology and biomedical applications, aiming to develop novel therapeutic strategies that improve human health and address critical challenges in modern medicine.

Notable Publications

Current mechanistic concepts in ischemia and reperfusion injury
Authors: Meng-Yu Wu, Giou-Teng Yiang, Wan-Ting Liao, Andy Po-Yi Tsai, Yeung-Leung Cheng, Pei-Wen Cheng, Chia-Ying Li, Chia-Jung Li
Journal: Cellular Physiology and Biochemistry
Year: 2018

Application of time series analysis in modelling and forecasting emergency department visits in a medical centre in Southern Taiwan
Authors: Wang-Chuan Juang, Sin-Jhih Huang, Fong-Dee Huang, Pei-Wen Cheng, Shue-Ren Wann
Journal: BMJ Open
Year: 2017

Resveratrol decreases fructose‐induced oxidative stress, mediated by NADPH oxidase via an AMPK‐dependent mechanism
Authors: Pei‐Wen Cheng, Wen‐Yu Ho, Yu‐Ting Su, Pei‐Jung Lu, Bo‐Zone Chen, Wen‐Han Cheng, Wen‐Hsien Lu, Gwo‐Ching Sun, Tung‐Chen Yeh, Michael Hsiao, Ching‐Jiunn Tseng
Journal: British Journal of Pharmacology
Year: 2014

Angiotensin II inhibits neuronal nitric oxide synthase activation through the ERK1/2-RSK signaling pathway to modulate central control of blood pressure
Authors: Wen-Han Cheng, Pei-Jung Lu, Wen-Yu Ho, Che-Se Tung, Pei-Wen Cheng, Michael Hsiao, Ching-Jiunn Tseng
Journal: Circulation Research
Year: 2010

Effect of resveratrol on reactive oxygen species-induced cognitive impairment in rats with angiotensin II-induced early Alzheimer’s disease
Authors: Yu-Te Lin, Yi-Chung Wu, Gwo-Ching Sun, Chiu-Yi Ho, Tzyy-Yue Wong, Ching-Huang Lin, Hsin-Hung Chen, Tung-Chen Yeh, Chia-Jung Li, Ching-Jiunn Tseng, Pei-Wen Cheng
Journal: Journal of Clinical Medicine
Year: 2018

Caffeine intake improves fructose-induced hypertension and insulin resistance by enhancing central insulin signaling
Authors: Tung-Chen Yeh, Chun-Peng Liu, Wen-Han Cheng, Bo-Rong Chen, Pei-Jung Lu, Pei-Wen Cheng, Wen-Yu Ho, Gwo-Ching Sun, Jau-Cheng Liou, Ching-Jiunn Tseng
Journal: Hypertension
Year: 2014

Conclusion 

Prof. Pei-Wen Cheng exemplifies dedication to advancing scientific knowledge and fostering innovation in medical research. Her career journey from doctoral studies to professorship reflects her commitment to academic excellence and impactful research. With a focus on nanomedicine, pharmacology, and metabolic syndrome, she continues to push the boundaries of biomedical science. Her contributions extend beyond research, encompassing teaching, mentorship, and international collaborations that strengthen academic networks. As a professor, she remains committed to inspiring future scientists while pursuing groundbreaking discoveries. Prof. Cheng’s work demonstrates how multidisciplinary approaches can contribute to improved healthcare outcomes and scientific advancement on a global scale.